web analytics
Phase 3 analytical method was developed with HPLC method validation | Velesco Pharma

Analytical Method Challenge 1

Method Development and Validation of Challenging Drugs


A client came to Velesco with a peptide drug in preserved solution. The current analytical method was in use for the drug without preservative. The client needed a Phase 3 method to quantify both the drug and the preservative, with improved resolution of a closely eluting impurity and shorter run time.

The preservative was well separated in the current analytical method, but was over the maximum detection capacity. Also, several lots of commercially available preservative had an impurity that co-eluted with the active drug peak.  


Velesco solution:

  • Velesco developed a new HPLC method using an ion pair reagent that provided resolution of the preservative impurity from the active peak, improved resolution of the active impurity, and reduced the retention time by nine minutes. 
  • The preservative quantitation was successfully performed in the same run by using a second collection wavelength to bring the peak onto scale.
  • Velesco performed the method validation for the two strengths of drug formulation.


During method validation, several new drug product strengths were introduced. Research data showed that the drug product could not be reliably quantified against a one-point standard curve to meet Phase 3 needs. In addition, the sample and standard matrix needed to match exactly for accurate quantitation.


Velesco solution:

  • Velesco successfully re-validated this Phase 3 method for the new strengths of drug product using a matching standard for each sample. 
  • The matching standard contained equivalent preservative and excipient concentrations to the sample.
  • All method validations passed Phase 3 requirements.

Back to analytical development case studies

News and Events

Pace® Life Sciences Acquires Velesco Pharmaceutical Services, Expanding Capabilities in Drug Development Services

Read the Press Release!

Dave Barnes, Ph.D. CEO/CSO is a featured speaker for the webinar Topical Formulation: Selection of Excipients and Better Process Understanding for Success in Commercial Manufacturing. Webinar recording available now.

View Recording!

Newly Acquired DEA Analytical Laboratory License. We are licensed to use schedules 2, 2N, 3, 3N, 4, and 5.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Gerry Cox, Founder and Chief Operating Officer at Velesco Pharmaceutical Services.

Roundtable: M&A trends in CDMO - Molecule to Market

New Velesco Pharma clinical manufacturing facility begins operations.

Read the press release here.

Lisa Crandall, MS, and Peter Angus, PhD, spoke with Pharmaceutical Technology about the best practices in stability testing.

Read the interview here.

Velesco has expanded our analytical facilities in a new Wixom, Michigan location with the help of the Bank of Ann Arbor Technology Industry Group.

Read the press release here.

CEO Dave Barnes has been published in a new Pharmoutsourcing article on Clinical Trial Materials and Manufacturing!

1 new job postings! Careers

Velesco's work published

Formulation Development & Manufacturing:
Using a Single Provider Reduces Costs & Risk
Read it here.

Follow Velesco

LinkedIn IN Icon 25px Google+ Follow VelescoPharma on Twitter FB FindUsOnFacebook 100